Circulating Levels of Insulin-Like Growth Factor (IGF) Binding Protein-1 and -3 in Aging Men: Relationships to Insulin, Glucose, IGF, and Dehydroepiandrosterone Sulfate Levels and Anthropometric Measures1
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Reduced secretion of GH and production of insulin-like growth factor I (IGF-I) contribute to altered body composition in human aging. IGF-binding proteins (IGFBPs) are important modulators of IGF action, yet little is known regarding their role and regulation in aging. Accordingly, we measured levels of IGFBP-1, an important short term modulator of IGF bioavailability that is suppressed by insulin, and levels of IGFBP-3, the major circulating IGF carrier protein, and examined their relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures in old (63-89 yr) and young (23-39 yr) men. Serum levels of IGFBP-1 were increased 3-fold in old vs. young men despite high insulin levels in elders. Nevertheless, IGFBP-1 and insulin levels correlated in old and young men (r = - 0.49; P < 0.002 and r = -0.42; P < 0.025), suggesting that insulin continues to play an important role in the regulation of IGFBP-1 in aging. Glucose levels also were significantly inversely related to IGFBP-1 in old and young men (r = 0.37; P = 0.02 and r = -0.49; P < 0.01), and this relationship was not accounted for by the effect of insulin. IGF-I levels were reduced by 33% in elders (P < 0.001) and correlated with IGFBP-1 levels among old (r = -0.40; P < 0.01), but not young, men, indicating that low GH secretion and/or IGF-I production may contribute to the elevation of IGFBP-1 levels in aging. IGFBP-3 levels were reduced among elders, but not to the same extent as IGF-I, resulting in a relative excess of IGFBP-3 in elders (IGFBP-3/IGF-I ratio, 20.1 +/- 0.9 vs. 15.4 +/- 1.0; P < 0.001). The IGFBP-3/IGF-I ratio correlated with IGF-I levels in young and old men (r = -0.79; P < 0.001 and r = -0.82; P < 0.001), indicating that diminished GH secretion also may contribute to a relative excess of IGFBP-3 among elders. Dehydroepiandrosterone sulfate levels were low in elders, but did not correlate with IGF, IGFBP, insulin, or glucose levels in either age group. Serum levels of IGFBP-1 (but not IGF-I or -II or IGFBP-3) correlated with body mass index and upper arm fat and muscle areas in elders. These relationships were accounted for by the effects of insulin, suggesting that regulation of IGFBP-1 by insulin may play a role in determining body composition in aging. We conclude that insulin remains an important determinant of IGFBP-1 levels in elders, that the fasting glucose level is also a significant determinant of IGFBP-1 in both old and young subjects, and that reduced secretion of GH may contribute to impaired anabolism in aging through multiple mechanisms, including reduced production of IGF-I and alterations in circulating levels of both IGFBP-1 and -3. These findings are consistent with the concept that alterations in IGFBP levels may contribute to changes in IGF bioavailability and body composition in aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
ORENTREICH, N., BRIND, J. L., RIZER, R. L., & VOGELMAN, J. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-3-551 · Cited by 1,349
Human growth hormone and human aging
CORPAS, E., HARMAN, S. M., & BLACKMAN, M. R. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-1-20 · Cited by 911
Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
Morales, A. J., Nolan, J. J., Nelson, J. C., & Yen, S. S. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.6.7515387 · Cited by 841
NESTLER, J. E., BARLASCINI, C. O., CLORE, J. N., & BLACKARD, W. G. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-66-1-57 · Cited by 414
Role of Glucose Effectiveness in the Determination of Glucose Tolerance
Best, J. D., Kahn, S. E., Ader, M., Watanabe, R. M., Ni, T. C., & Bergman, R. N. (1996) · Diabetes Care · doi:10.2337/diacare.19.9.1018 · Cited by 290
Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1
Powell, D. R., Suwanichkul, A., Cubbage, M. L., DePaolis, L. A., Snuggs, M. B., & Lee, P. D. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55144-9 · Cited by 217
Cited by
Serum levels of insulin-like growth factor I and its binding proteins in health and disease
Juul, A. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00038-8 · Cited by 467
Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness
Ryall, J. G., Schertzer, J. D., & Lynch, G. S. (2008) · Biogerontology · doi:10.1007/s10522-008-9131-0 · Cited by 423
“Benbassat et al. (1997) examined the protein levels of circulating IGFBPs and reported a two-fold increase in IGFBP1 and an *15% decrease in IGFBP3, in old compared with young men (Table 1).”
BackgroundResultInfluentialEffect of GH/IGF-1 on Bone Metabolism and Osteoporsosis
Locatelli, V., & Bianchi, V. E. (2014) · International Journal of Endocrinology · doi:10.1155/2014/235060 · Cited by 307
Vasan, R. S., Sullivan, L. M., D'Agostino, R. B., Roubenoff, R., Harris, T., Sawyer, D. B., Levy, D., & Wilson, P. W. F. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00007 · Cited by 279
Allen, N. E., Appleby, P. N., Kaaks, R., Rinaldi, S., Davey, G. K., & Key, T. J. (2003) · Cancer Causes & Control · doi:10.1023/a:1022518321634 · Cited by 104
Metadata
- Authors
- Benbassat, C. A., Maki, K. C., & Unterman, T. G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-05
- Volume
- 82
- Issue
- 5
- Pages
- 1484-1491
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2053454043
- Cited by
- 108
- References
- 7
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.